Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 8Neoplasms 4Pain, Postoperative 2Hemangioma, Capillary 2Carcinoma, Hepatocellular 2Anxiety Disorders 2Weight Loss 1Vomiting 1Urinary Incontinence, Stress 1Urinary Incontinence 1Shoulder Pain 1SCLC, Limited Stage 1Respiratory Aspiration 1Psychomotor Agitation 1Prostatic Neoplasms 1Premature Birth 1Polycystic Ovary Syndrome 1Pediatric Obesity 1Ovarian Cysts 1Obesity 1Neuromuscular Diseases 1Neuroblastoma 1Nasopharyngeal Carcinoma 1Myofibroma 1Myelodysplastic Syndromes 1Myasthenia Gravis 1Multiple Myeloma 1Menstruation Disturbances 1Lymphoma, Follicular 1Lung Neoplasms 1

Interventions

rozanolixizumab 10zilucoplan 8efgartigimod alfa 8Rituximab 7Cyclophosphamide 7telitacicept 6fludarabine 6eculizumab 5Prednisone 5ravulizumab 4Pyridostigmine Bromide 4Immunoglobulins, Intravenous 4Hizentra 4Tacrolimus 3Mycophenolic Acid 3HBM9161 3Amifampridine 3thymoglobulin 2inebilizumab 2Prednisolone 2Exercise 2tofacitinib 1tocilizumab 1talquetamab 1satralizumab 1sargramostim 1rhoA GTP-Binding Protein 1remibrutinib 1prednylidene 1iscalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Myasthenia Gravis × Population Groups × Clear all
NCT06827587 2025-02-14

Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis

First Affiliated Hospital of Wenzhou Medical University

Phase NA Not yet recruiting
60 enrolled

Autoimmune Diseases, Myasthenia Gravis, Neuromuscular Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡